Odne expands launch activities in US, appoints Steve Fanning

Search Dental Tribune

Odne expands launch activities in the US, appoints Steve Fanning as member of the board

Odne has recently launched a priority access programme for its innovative Root Preservation Therapy in the US, offering endodontists the opportunity to be among the first users of Odne’s devices and to provide valuable use-related and scientific feedback. (Image: Microgen/Shutterstock)
Odne

Odne

Tue. 18. June 2024

save

ZURICH, Switzerland: Swiss-based start-up Odne, which was founded in 2018 and develops endodontic products, has recently launched a priority access programme for its innovative Root Preservation Therapy at this year’s annual meeting of the American Association of Endodontists in Los Angeles in the US. In addition, the company announced the appointment of Steve Fanning as an independent board member.

The priority access programme will form the core of Odne’s scientific and clinical community. One goal of the programme is to create a clinical case registry to collect further knowledge on the clinical use of Odne’s devices for root canal treatment. Participating endodontists will have the opportunity to be among the first users of Odne’s devices and to provide valuable use-related and scientific feedback. More information on how to become a priority access programme associate can be found here.

New independent board member Steve Fanning says he is excited about his new position at Odne. (Image: Steve Fanning)

Steve Fanning brings over 25 years of commercial and general management experience in healthcare to his new position and has previously held managing positions at Danaher (now Envista Holdings) and Henry Schein.

Dr Andreas Schmocker, CEO of Odne, commented on the appointment of Fanning in a company press release, saying: “We are currently in the process of launching the Odne system in the US and Steve’s background with building businesses in endodontics will be a tremendous asset as we look to expand Odne’s presence.”

Fanning said that he was honoured and excited to be collaborating with Odne to bring innovation to endodontics. “The Odne system has the potential to empower clinicians to perform endodontic procedures with more confidence and enable them to provide patients with better outcomes. I couldn’t be more proud of the team and the work they are doing,” he added.

Odne’s technology platform for root canal debridement and obturation

OdneClean offers a non-instrumented approach to root canal debridement. Its 190 µm debridement tip creates a hydrodynamic cavitation cloud using saline solution inside the root canal, and the cavitation jet removes debris inside the canals and tubules. US Food and Drug Administration (FDA) clearance for OdneClean is expected in the second half of this year.

OdneFill is the first light-polymerised, injectable endodontic obturation material cleared by the FDA. OdneFill is a hydrogel, a class of biomaterials known for its excellent biocompatibility and hydrophilicity. Owing to its water-like viscosity and ultra-high hydrophilicity in its unpolymerised state, it can flow into complex root canal structures, such as isthmuses, deltas and C-shaped canals. Once polymerised with OdneCure, a microlaser for polymerisation inside the root canal, it provides gap-free root canal sealing and long-term obturation.*

More information about the company’s products can be found at odne.co.

Editorial note:

* OdneFill and OdneCure are cleared for use in the US only. All other Odne devices are currently in development and have not received approval for clinical use.

Topics:
Tags:
To post a reply please login or register
advertisement
advertisement